Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. The company is headquartered in New York City, New York and currently employs 362 full-time employees. The company went IPO on 2019-05-14. The firm is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. The company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.
Follow-Up Questions
Who is the CEO of Immunovant Inc?
Dr. Eric Venker is the Chief Executive Officer of Immunovant Inc, joining the firm since 2020.
What is the price performance of IMVT stock?
The current price of IMVT is $25.21, it has increased 2.15% in the last trading day.
What are the primary business themes or industries for Immunovant Inc?
Immunovant Inc belongs to Biotechnology industry and the sector is Health Care
What is Immunovant Inc market cap?
Immunovant Inc's current market cap is $4.3B
Is Immunovant Inc a buy, sell, or hold?
According to wall street analysts, 16 analysts have made analyst ratings for Immunovant Inc, including 8 strong buy, 9 buy, 5 hold, 0 sell, and 8 strong sell
